Genetic Technologies

The company said it is considering all transactions that would boost shareholder value including a merger or sale of its assets.

The Australian molecular diagnostics firm received 265 test samples during the quarter, including 140 tests issued to Ohio State University as part of an agreement.  

The company said it has been notified that its shares fail to meet the Nasdaq's $1 minimum bid price requirement.

The company is switching from an insurance-based model to a direct patient self-pay system for its BrevaGenplus breask cancer risk assessment assay.

The company plans to use the proceeds to expand its breast cancer risk test and to develop and commercialize a risk assessment test for colorectal cancer.

The technology involves analyzing susceptibility SNPs in order to predict a patient's likelihood of developing colorectal cancer.

The Australian firm regained compliance with a listing rule requiring a minimum $2.5 million in stockholder equity.

The Australian MDx firm will use the financing to support its medium-term capital needs and the commercialization of its BrevaGenplus test.

The Australian molecular diagnostics firm will use the facility to further commercialize its breast cancer test in the US.

The Australian company will use proceeds to ramp up the commercialization of its breast cancer test.